Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124–137.
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.
Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170–183.
Botto H, Neuzillet Y, Lebret T, Camparo P, Molinie V, Raynaud J-P. High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol 2011; 186: 1400–1405.
Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 52–58.
Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, Allory Y et al. Low pretreatment total testosterone (<3 ng/ml) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int 2011; 107: 1400–1403.
Dai B, Qu Y, Kong Y, Ye D, Yao X, Zhang S et al. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer. BJU Int 2012; 110: E667–E672.
Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008; 72: 1240–1245.
Imamoto T, Suzuki H, Yano M, Kawamura K, Kamiya N, Araki K et al. The role of testosterone in the pathogenesis of prostate cancer. Int J Urol 2008; 15: 472–480.
Kim HJ, Kim BH, Park CH, Kim CI. Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence. Korean J Urol 2012; 53: 9–13.
Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670–1675.
Cabral PHO, Iwamoto MW, Fanni VSS, Barros L, da R, Cardoso SN, Mello LF et al. Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer. Int Braz J Urol 2013; 39: 173–181.
Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173: 1935–1937.
Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174: 2178–2180.
Salonia A, Abdollah F, Capitanio U, Gallina A, Suardi N, Briganti A et al. Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World J Urol 2013; 31: 275–280.
Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007; 52: 696–701.
Thickman D, Speers WC, Philpott PJ, Shapiro H. Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer. J Urol 1996; 156: 110–113.
Moreira Leite KR, Camara-Lopes LHA, Dall’Oglio MF, Cury J, Antunes AA, Sañudo A et al. Upgrading the Gleason score in extended prostate biopsy: implications for treatment choice. Int J Radiat Oncol Biol Phys 2009; 73: 353–356.
Müntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 2008; 53: 767–775; discussion 775–776.
Pinthus JH, Witkos M, Fleshner NE, Sweet J, Evans A, Jewett MA et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 2006; 176: 979–984; discussion 984.
Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL et al. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol 2006; 176: 2453–2458; discussion 2458.
Grossfeld GD, Chang JJ, Broering JM, Li YP, Lubeck DP, Flanders SC et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001; 165: 851–856.
Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology 2008; 72: 177–182.
Rapiti E, Schaffar R, Iselin C, Miralbell R, Pelte M-F, Weber D et al. Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study. BMC Urol 2013; 13: 19.
Léon P, Seisen T, Cussenot O, Drouin SJ, Cattarino S, Compérat E et al. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer. Urol Oncol 2015; 33: 384.e21–7.
Fiet J, Giton F, Fidaa I, Valleix A, Galons H, Raynaud J-P. Development of a highly sensitive and specific new testosterone time-resolved fluoroimmunoassay in human serum. Steroids 2004; 69: 461–471.
Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract 2002; 8: 440–456.
Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507–514.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228–1242.
Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI et al. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 2009; 133: 1568–1576.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C et al. A Contemporary Prostate Cancer Grading System: a validated alternative to the Gleason score. Eur Urol 2015 (doi: 10.1016/j.eururo.2015.06.046).
Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL et al. Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000; 56: 730–734.
Kramer MS, Feinstein AR. Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 1981; 29: 111–123.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159–174.
Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005; 47: 308–312.
Røder MA, Christensen IJ, Berg KD, Gruschy L, Brasso K, Iversen P. Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int 2012; 109: 520–524.
D’Elia C, Cerruto MA, Cioffi A, Novella G, Cavalleri S, Artibani W. Upgrading and upstaging in prostate cancer: from prostate biopsy to radical prostatectomy. Mol Clin Oncol 2014; 2: 1145–1149.
Karakiewicz PI, Chun FK-H, Gallina A, Suardi N, Briganti A, Erbersdobler A et al. Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sum. J Endourol 2008; 22: 533–538.
Reis LO, Sanches BCF, de Mendonça GB, Silva DM, Aguiar T, Menezes OP et al. Gleason underestimation is predicted by prostate biopsy core length. World J Urol 2015; 33: 821–826.
Seisen T, Roudot-Thoraval F, Bosset PO, Beaugerie A, Allory Y, Vordos D et al. Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason≤6 on biopsy cores. World J Urol 2015; 33: 787–792.
Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A et al. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology 2009; 73: 1087–1091.
Miyake H, Kurahashi T, Takenaka A, Hara I, Fujisawa M. Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores. Urol Int 2007; 79: 302–306.
Seles M, Gutschi T, Mayrhofer K, Fischereder K, Ehrlich G, Gallé G et al. Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate. BJU Int 2015 (doi: 10.1111/bju.13108).
Mian BM, Lehr DJ, Moore CK, Fisher HAG, Kaufman RP, Ross JS et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology 2006; 67: 379–383.
Kamrava M, Kishan AU, Margolis DJ, Huang J, Dorey F, Lieu P et al. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Pract Radiat Oncol 2015 (doi: 10.1016/j.prro.2015.04.006).
Arsov C, Becker N, Rabenalt R, Hiester A, Quentin M, Dietzel F et al. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. J Cancer Res Clin Oncol 2015; 141: 2061–2068.
Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer 2013; 119: 3992–4002.
Neuzillet Y, Raynaud J-P, Lebret T, Pichon A, Radulescu C, Molinie V et al. Obesity and hypogonadism are associated with an increased risk of predominant Gleason 4 pattern on radical prostatectomy specimen. Horm Mol Biol Clin Investig 2015; 22: 101–109.
Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS et al. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int 2012; 110: E494–E499.
Mearini L, Nunzi E, Ferri C, Bellezza G, Lolli C, Porrozzi C et al. Use of the Prostate Health Index for the detection of aggressive prostate cancer at radical prostatectomy. Urol Int (e-pub ahead of print 17 March 2015).
Gleason DF. Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Urology 1996; 47: 289–291.
San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int 2014; 114: 229–235.